- Home
- MCS vs AVTX Comparison
MCS vs AVTX Comparison
Compare MCS & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCS | AVTX |
|---|---|---|
| Founded | 1935 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.5M | 710.1M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MCS | AVTX |
|---|---|---|
| Price | $27.14 | $7.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $32.50 | ★ $34.80 |
| AVG Volume (30 Days) | 178.8K | ★ 2.8M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,458,000.00 | $27,813,137.00 |
| Revenue This Year | $15.94 | N/A |
| Revenue Next Year | $1.30 | N/A |
| P/E Ratio | $34.62 | ★ N/A |
| Revenue Growth | 3.11 | ★ 2312.27 |
| 52 Week Low | $14.63 | $6.53 |
| 52 Week High | $32.42 | $24.27 |
Technical Indicators
Market Signals| Indicator | MCS | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 29.16 |
| Support Level | $26.30 | $6.53 |
| Resistance Level | $29.19 | $20.54 |
| Average True Range (ATR) | 0.94 | 0.73 |
| MACD | -0.12 | 0.13 |
| Stochastic Oscillator | 29.13 | 11.20 |
Price Performance
Historical ComparisonAbout MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.